ClinicalTrials.gg
RecruitingNCT06489249Updated Oct 29, 2026

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use

An Early Phase 1 interventional study of Placebo and Salsalate 750 MG Oral Tablet [DISALCID] in Electronic Cigarette Use, Endothelial Dysfunction and Inflammation, sponsored by University of Iowa. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of Iowa · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 29, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 288 studies in Vaping with a site in United States — 66 open to participants now, 74 under way, 1 of them phase 3. Vaping · United States.

Planned enrollment
210th of 258
24 · median 71
Started
2024
with 30 others
Phase 1
16 of 288
7 open now
Primary completion
2027-04
later than 27 of 73 live
Registered
220th of 288
by date

Among the 288 studies in Vaping with a site in United States, this one is the 210th largest by planned enrollment of the 258 interventional ones that give a count, is one of 31 that started in 2024, is one of 16 in phase 1, reaches primary completion later than 27 of the 73 other live ones, and was the 220th registered.

Vaping

404 studies on the registry are indexed under Vaping; 97 are open to participants now.

Browse Vaping studies →

Open to participants now

66 of the 288 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 24 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 288 studies in Vaping with a site in United States, or all of them as a file.
02

Study summary

The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.

03

Conditions studied

  • Electronic Cigarette Use
  • Endothelial Dysfunction
  • Inflammation
04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 24 years of age
  • no history of e-cigarette use (control) OR current with 6 months or more history of e-cigarette use (chronic use).

Exclusion criteria

Exclusion Criteria:

  • tobacco cigarette use (current or history of)
  • use of stimulant drugs
  • skin diseases
  • cardiovascular disease
  • diagnosed or suspected hepatic or metabolic disease including diabetes
  • statin or other cholesterol-lowering medication
  • antihypertensive medication
  • current pregnancy or breastfeeding
  • blood pressure greater than or equal to 140mmHg systolic and/or greater than or equal to 90mmHg diastolic
  • allergy to materials used during the experiment
  • known allergies to salsalate or other study drugs
05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Placebo then Salsalate

    Placebo oral table twice daily for 4 days prior to experimental testing followed by 14 day washout period and then salsalate oral tablet 1500mg twice daily for 4 days prior to experimental testing.

    Drug: Placebo · Drug: Salsalate 750 MG Oral Tablet [DISALCID]

  • Experimental
    Salsalate then Placebo

    Salsalate oral tablet 1500mg twice daily for 4 days prior to experimental testing followed by 14 day washout period and then placebo oral tablet twice daily for 4 days prior to experimental testing.

    Drug: Placebo · Drug: Salsalate 750 MG Oral Tablet [DISALCID]

Interventions

06

What researchers measure

Primary outcomes

  1. Microvascular endothelial function (Cutaneous conductance, %maximum) following salsalate treatment compared to placebo treatment

    Endothelium-dependent vasodilation assessed as cutaneous conductance response (cutaneous conductance = local red blood cell flux/mean arterial pressure; %maximum) to local heating of the skin (42 degrees Celcius).

    Time frame: a total of 2 times throughout the study (approximately 4 weeks): 1) at the completion of 4 days of oral salsalate treatment, and 2) at the completion of 4 days of placebo treatment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2024 (actual). Primary completion is estimated for Apr 2027, 32 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jun 2026 → Apr 2027 and completion Oct 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 5, 2024
StartActual
Aug 15, 2024
Primary completionEst.
Apr 2027was Jun 2026
CompletionEst.
Jun 2027was Oct 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Apr 2027
Oct 29, 2026
Study completion
Oct 2026→Jun 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Jun 2026→Apr 2027
    Study completion Oct 2026→Jun 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06489249
Lead sponsor
University of Iowa
Responsible party
Anna Stanhewicz, PhD (Assistant Professor, University of Iowa) — Principal investigator
First posted
Jul 5, 2024
Start date
Aug 15, 2024
Primary completion
Apr 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Anna Stanhewicz, PhD
Contact
anna-stanhewicz@uiowa.edu
3194671732

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salicylsalicylic acid

Start the discussion